Arcturus Therapeutics Ltd (NASDAQ:ARCT) Director Peter C. Farrell acquired 9,113 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was bought at an average price of $10.94 per share, for a total transaction of $99,696.22. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of ARCT traded down $0.26 during mid-day trading on Wednesday, hitting $10.31. 66,102 shares of the company’s stock were exchanged, compared to its average volume of 61,703. The firm has a fifty day moving average of $10.45 and a two-hundred day moving average of $7.52. Arcturus Therapeutics Ltd has a twelve month low of $4.11 and a twelve month high of $15.50. The stock has a market cap of $147.12 million, a price-to-earnings ratio of -4.77 and a beta of 2.36. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 2.43.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, August 15th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.46. Arcturus Therapeutics had a negative net margin of 50.32% and a negative return on equity of 112.75%. The company had revenue of $10.15 million for the quarter, compared to analyst estimates of $4.01 million. On average, equities analysts predict that Arcturus Therapeutics Ltd will post -1.94 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Highline Capital Management L.P. lifted its position in Arcturus Therapeutics by 356.6% during the second quarter. Highline Capital Management L.P. now owns 217,866 shares of the biotechnology company’s stock worth $2,057,000 after purchasing an additional 170,152 shares during the period. BlackRock Inc. lifted its position in Arcturus Therapeutics by 23.5% during the second quarter. BlackRock Inc. now owns 23,548 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 4,480 shares during the period. JPMorgan Chase & Co. bought a new stake in Arcturus Therapeutics during the second quarter worth about $128,000. ARK Investment Management LLC lifted its position in Arcturus Therapeutics by 8.3% during the second quarter. ARK Investment Management LLC now owns 1,004,368 shares of the biotechnology company’s stock worth $9,481,000 after purchasing an additional 77,224 shares during the period. Finally, Nikko Asset Management Americas Inc. lifted its position in Arcturus Therapeutics by 102.8% during the second quarter. Nikko Asset Management Americas Inc. now owns 129,974 shares of the biotechnology company’s stock worth $1,227,000 after purchasing an additional 65,875 shares during the period. Institutional investors own 13.32% of the company’s stock.

ARCT has been the topic of several analyst reports. Chardan Capital set a $18.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. Zacks Investment Research lowered shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright set a $18.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 16th. ValuEngine lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Finally, Brookline Capital Management restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $15.33.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Recommended Story: Ex-Dividend

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.